<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5012">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096302</url>
  </required_header>
  <id_info>
    <org_study_id>GO-INF-010</org_study_id>
    <nct_id>NCT02096302</nct_id>
  </id_info>
  <brief_title>The Effects of an Infant Formula Containing Probiotic CECT7210 on Gastrointestinal Health</brief_title>
  <acronym>GO-INF</acronym>
  <official_title>Evaluar el Efecto de Una fórmula Infantil Enriquecida Con el probiótico CECT7210 Sobre la Incidencia de Infecciones Gastrointestinales</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harrison Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an infant formula supplemented with a new
      probiotic CECT7210, is effective in reducing the incidence of infections, specially the
      gastrointestinal ones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a multicenter, controlled, randomized, prospective, parallel, double-blinded study to
      evaluate the effect of an infant formula containing a new probiotic, Bifidobacterium longum
      biovar infantis CECT7210, on the incidence of diarrhea in healthy infants born at term.
      Infants will be randomized to take an standard infant formula or the infant formula with the
      probiotic CECT7210 during 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in diarrhea incidence</measure>
    <time_frame>At 4th, 8th, 12th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between diarrhea incidence amongst groups from baseline to 12th weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in infections incidence</measure>
    <time_frame>At 4th, 8th, 12th weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between rate of infections or duration amongst groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in microbiota</measure>
    <time_frame>At 4th, 8th, 12th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between faecal bacterial populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Immunoglobulin A secretor (IgAs)</measure>
    <time_frame>At  4th and 12th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between faecal IgAs amongst groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>At 4th, 8th and 12th weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate gastrointestinal tolerability of both study formulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>At 4th, 8th and 12th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare anthropometric measurements between probiotic CECT7210 formula group and standard group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Gastrointestinal Diseases</condition>
  <arm_group>
    <arm_group_label>Experimental Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant formula with a novel probiotic CECT7210</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard infant formula without probiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Infant Formula with a novel probiotic CECT7210</intervention_name>
    <description>Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.</description>
    <arm_group_label>Experimental Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard formula</intervention_name>
    <description>Standard formula without probiotics</description>
    <arm_group_label>Standard Formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full-term healthy newborns (&gt;= 37 weeks)

          -  Birth weight between &gt;=2.500g and &lt;=4.500g)

          -  Normal growth curve (between 3-97 percentiles)

          -  0-60 days of age on enrolment

          -  Maximum 30 days of breastfeeding

          -  Exclusively infant formula on enrolment

          -  Breastfeeding or infant formula with pre/probiotics feeding stopped 15 days before
             enrolment

          -  Parents or caregivers agree to exclude any source of prebiotics or probiotics during
             the study

          -  Parents or caregivers agree to follow-on the study 12 weeks

          -  Informed consent signed ( Parent/Legal representative)

        Exclusion Criteria:

          -  Congenital illness or malformation that may affect infant feeding and /or normal
             growth

          -  Significant pre-natal or post-natal diseases

          -  Infant's family history of atopy

          -  Any pathology related to the immune or gastrointestinal system.

          -  Suspected or known allergy to cow's milk protein

          -  Infants receiving pre or probiotics within less than 15 days prior to enrolment

          -  Infant's family who in the investigator's assessment cannot be expected to comply
             with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Polanco, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz, Madrid (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Escribano, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Reus, Reus, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Closa, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Joan XXIII de Tarragona, Tarragona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Infant Formula</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Bifidobacterium longum biovar infantis CECT7210</keyword>
  <keyword>Growth</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
